Sympathetic nerve ablation slows ACC growth in vivo. (A–D) AH43a and AH45b tumor volumes from mice treated with 6-OHDA, cervical sympathectomy, propranolol, or sgADRB2 knockdown and NT control at week 3. (E–G) NE concentrations in AH43a and AH45b tumors treated with 6-OHDA, cervical sympathectomy, and propranolol. (H–J) TH⁺ nerves in AH43a and AH45b tumors and quantification of the percentage TH⁺ nerves out of all Tubb3⁺ nerves following propranolol, 6-OHDA, cervical sympathectomy, and sgADRB2 and NT control tumors of AH43a and AH45b at week 3. Scale bar: 50 μm. (K–N) Immunostaining and quantification of CD31⁺ microvessel length per DAPI⁺ area in AH43a and AH45b tumors treated with propranolol, 6-OHDA, cervical sympathectomy, or NT and sgADRB2 tumors of AH43a and AH45b at week 3. Scale bar: 50 μm. Data are either representative of or pooled from at least two independent experiments with n from 3 to 25 (A–C, E–G, I, J, L, and N) or one experiment (D). P values were determined by Student’s t test (A–G, J, and N), one-way ANOVA, and Fisher’s LSD test (I and L). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns: not significant.